Progenics Pharmaceuticals, Inc.
(NASDAQ : PGNX)

( )
PGNX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -6.73%146.810.0%$1534.10m
OCGNOcugen, Inc. -4.19%9.600.0%$1069.86m
NVAXNovavax, Inc. -14.27%205.9992.9%$909.19m
AMGNAmgen, Inc. -0.60%225.691.3%$548.32m
VRTXVertex Pharmaceuticals, Inc. 0.80%212.061.9%$521.91m
REGNRegeneron Pharmaceuticals, Inc. -1.77%454.862.7%$509.91m
ILMNIllumina, Inc. -1.23%441.013.5%$504.66m
GILDGilead Sciences, Inc. 0.88%63.011.0%$479.35m
ALXNAlexion Pharmaceuticals, Inc. -1.05%150.372.0%$354.39m
BNGOBionano Genomics, Inc. -3.66%9.480.0%$340.06m
BIIBBiogen, Inc. -1.24%269.851.7%$329.36m
CRSPCRISPR Therapeutics AG -0.37%129.770.6%$302.39m
EXASEXACT Sciences Corp. -2.72%136.3918.4%$253.67m
SGENSeagen Inc. 0.76%153.715.8%$214.53m
VXRTVaxart, Inc. -5.43%7.140.0%$189.51m

Company Profile

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.